Heterogeneity of Ex Vivo Tumor Responses in Ovarian Cancer Tissues
Cancer Reports · 2026-06 · 9 (6)
DOI: 10.1002/cnr2.70554 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, online erschienen am 14.06.2026. Verfasst von Chiara Maestri und 7 weiteren Autor:innen. Beteiligte Einrichtung: SageMedic Corp, Redwood City, California, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SageMedic Corporation.
Abstract (Originalsprache)
Background
Advanced‐stage ovarian cancers exhibit significant variability in responses to standard chemotherapy ranging from platinum‐refractory to platinum‐sensitive cancers. While genomic testing reveals tissue heterogeneity, it rarely provides actionable data for guiding therapy.
Aims
To evaluate the heterogeneity of ex vivo drug responses in primary ovarian cancer tissues using a functional profiling platform, and to assess the platform's potential for guiding personalized therapy selection within current clinical practice. Methods and Results A functional profiling platform that creates 3D microtumors from fresh biopsies was used to enable ex vivo assessment of drug efficacy in a physiologically relevant model. Interpatient heterogeneity was quantified as the statistical variability of the EC 50 values, calculated using the ratio of upper and lower interdecile values. Seventeen ovarian cancer tissues were processed and exposed to NCCN‐recommended drugs and drug combinations. Drug efficacy demonstrated significant interpatient heterogeneity ( p < 0.001). Carboplatin and paclitaxel alone exhibited moderate heterogeneity (54‐fold and 42‐fold difference), while their combination showed higher heterogeneity (3880‐fold difference), suggesting synergy in certain samples but not in others. Gemcitabine exhibited the highest single‐agent heterogeneity across the cohort (1504‐fold difference), whereas doxorubicin and olaparib demonstrated more consistent responses but limited efficacy in many samples (20‐fold and 16‐fold difference).
Conclusion
These findings align with the clinically observed variability in patient responses, highlighting the platform's potential to optimize therapy selection and support patient‐centric care within the standard of care for ovarian cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SageMedic Corp, Redwood City, California, USA.
- International Institute of Molecular and Cell Biology, Warsaw, Poland.
- National University, San Diego, California, USA.
- Department of Women and Children's Health, Clinic of Gynecology and Obstetrics, University of Padova, Padova, Italy.
- University of Arizona College of Medicine, Phoenix, Arizona, USA.
- University of California San Francisco, San Francisco, California, USA.
ORCID-Profile: Chiara Maestri, Ivan Trus, Rajeshwar Nitiyanandan, Jahanvi Kumar, Ricardo J Parker, Orazio De Tommasi, William Cance, Christian Apfel
Förderung
- SageMedic Corporation
Zitieren
APA
Maestri, C., Trus, I., Nitiyanandan, R., Kumar, J., Parker, R. J., De Tommasi, O., Cance, W., & Apfel, C. (2026). Heterogeneity of Ex Vivo Tumor Responses in Ovarian Cancer Tissues. Cancer Reports, 9(6). https://doi.org/10.1002/cnr2.70554
Vancouver
Maestri C, Trus I, Nitiyanandan R, Kumar J, Parker RJ, De Tommasi O, et al. Heterogeneity of Ex Vivo Tumor Responses in Ovarian Cancer Tissues. Cancer Reports. 2026;9(6). doi:10.1002/cnr2.70554
BibTeX
@article{Maestri2026,
author = {Maestri, Chiara and Trus, Ivan and Nitiyanandan, Rajeshwar and Kumar, Jahanvi and Parker, Ricardo J and De Tommasi, Orazio and Cance, William and Apfel, Christian},
title = {Heterogeneity of Ex Vivo Tumor Responses in Ovarian Cancer Tissues},
journal = {Cancer Reports},
year = {2026},
volume = {9},
number = {6},
doi = {10.1002/cnr2.70554}
}
EUVIMED